About this Session:
One of the key ongoing challenges that DTx faces is attaining coverage from payors; during our first session, we hope to shed light on what payors are looking for clinically and economically (hint: it's evidence). Moderator: Jessica Hauflaire , COO, Digital Therapeutics Alliance Panelists: Julia Strandberg , Chief Commercial Officer, Pear Therapeutics Joe Perekupka , CEO, Freespira Jason Parent , Director, Clinical Innovation, Point32Health